Phase 2 N=29 Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
Multiple Myeloma
Primary: Maximum Tolerated Dose of Thalidomide — 1000; 1000 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=127 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
Hepatocellular Carcinoma · Liver Metastases · Cutaneous or Subcutaneous Lymph Node
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 2; 0; 1; 0 Participants
Phase 2 N=600 Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
SARS-CoV-2
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 95; 69; 72; 65 Participants
Phase 2 N=38 Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529
Hypertension, Pulmonary
Primary: Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) — 3; 13; 5; 10 Participants
Phase 2 N=36 Varenicline for Gait and Balance Impairment in Parkinson Disease
Parkinson Disease
Primary: Berg Balance Scale — 43.93; 41.14; 43.25; 45.13 score on a scale — p=0.05
Phase 2 N=33 A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects
Dental Caries
Primary: Safety of Multiple C16G2 Varnish Applications — 0; 0; 0; 0 Participants
Phase 2 N=80 68 Ga-PSMA for High Risk Prostate Cancer
Prostate Cancer · High Risk
Primary: Proportion of Patients With Lymph Node Involvement — 4; 28 Participants
Phase 2 N=41 Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Changes in mRNA Expression in Blood of STAT3, PPAR-ɣ, and STC-1 at T0 — 4.19; 7.58; 6.43; 11.32 delta Ct (amplification cycles) — p=0.22
Phase 2 N=28 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Fibrolamellar Carcinoma · Fibrolamellar Liver Cancer
Primary: Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6) — 0; 0; 0; 9 Participants
Phase 2 N=27 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
Phase 2 N=74 Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Lymphoma, Non-Hodgkin · Lymphoma, Nonhodgkin · Lymphoma, B-Cell
Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001
Phase 2 N=112 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Neuroblastoma · Medulloblastoma
Primary: Number of Participants With Related Adverse Events as a Measure of Safety and Tolerability — 45 Participants
Phase 2 N=112 Ganaxolone in Posttraumatic Stress Disorder (PTSD)
PTSD
Primary: Change From Baseline in Clinician-Administered Posttrautamtic Stress Disorder (PTSD) Scale (CAPS) to Week 6 — 65.78; 62.67; 63.2; 61.30 Scores on a scale
Phase 2 N=116 Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation
Leukemia
Primary: Median Time to Engraftment of Neutrophils — 11; 11 days
Phase 2 N=80 Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Bladder Cancer · High Risk Superficial
Primary: Response Rate — 62; 18 Participants